Guest guest Posted April 17, 2007 Report Share Posted April 17, 2007 Bravo, MSF! I already wrote to you about a meeting I'm going to later this week of the ABA. Sounds like I don't need to ask the question I thought I would. Anything you want me to ask the new ABA president? Cheers! [ ] Novartis Gleevec case Dear CML Colleagues, Thanks to all of you who wrote to encourage Novartis to drop their cases against the Indian government. For those of you interested, here's an update on the status of the two (rather arcane, I'm afraid) cases: The final hearings for the case related to the Novartis challenge to section 3d of the Indian Patent Act (which limits the grounds for patenting of new formulations of known compounds) concluded on April 4, 2007 in the Chennai High Court. The decision of the court on the case is pending and a date has not been set for when this will be handed down but it may occur before they go to recess in May or if not then it will be in June. This is the critical part of the case that MSF has been following. Currently nearly 500,000 people have written to Novartis or signed a petition calling on the company to drop the case. If the Novartis challenge is rejected by the high court then we hope that the public awareness and pressure that has been raised will lead the company to not appeal the decision in the supreme court. In that case the public health safeguards of the Indian patent act (section 3d) will remain intact. The second case related to the challenge by Novartis of the patent offices decision to reject an application on the new formulation of Imatinib Mesylate has been handed to an intellectual property appellate body that will now hear the case. This process has not begun. Warm regards to all, R Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.